IL17A and asthma: According to the results obtained in the previously mentioned murine models of asthma, the effect of brodalumab, a humanized anti-IL17 monoclonal antibody already approved in the treatment of psoriasis, was investigated in a randomized controlled trial (RCT) in non-selected patients with moderate-to-severe asthma (206).